Therapeutic strategy for low-risk thyroid cancer in Kanaji Thyroid Hospital.
It is well-known that differentiated thyroid carcinoma (DTC) has a generally indolent character and shows a favorable prognosis in comparison with many other carcinomas. The therapeutic strategy for patients with DTC in Japan has differed from that in Western countries. Total thyroidectomy followed by radioactive iodine (RAI) ablation has been standard in Western countries, whereas limited hemi-thyroidectomy and subtotal thyroidectomy has been extensively accepted in Japan. Papillary thyroid carcinoma (PTC) accounts for over 90% of all thyroid cancers in Japan. The majority of patients with PTC are categorized into a low-risk group on the basis of the recent risk-group classification schemes, and they show excellent outcomes. Several management guidelines for thyroid cancers have been published in Western countries. However, the optimal therapeutic options for PTC remain controversial, and high-level clinical evidence aimed at resolving these issues is lacking. Moreover, as socioeconomic differences in medical care exist, conventional policies for the treatment of PTC have differed between Japan and other countries. This review focuses on the special features of treatment in Japan for patients with low-risk DTC involving subtotal thyroidectomy without adjuvant therapies, rather than total thyroidectomy with RAI, with the aim of preserving quality of life. At our institution in Japan, we have had extensive experience with RAI treatment for high-risk DTC patients, and this represents a very rare situation. Here we introduce the therapeutic strategy for low-risk thyroid cancer in Japan, including the measures adopted at our institution.
Department of Surgery, Kanaji Thyroid Hospital, Tokyo 114-0015, Japan.
Makoto
M
Kammori
Tatsuya
T
Fukumori
Yoshiyuki
Y
Sugishita
Masae
M
Hoshi
Tetsu
T
Yamada
D018263:Adenocarcinoma, Follicular / Q000453:epidemiology / Q000601:surgery / Q000628:therapy; D002277:Carcinoma / Q000453:epidemiology / Q000601:surgery / Q000628:therapy; D002291:Carcinoma, Papillary; D006782:Hospitals, Special; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D007564:Japan / Q000453:epidemiology; D008197:Lymph Node Excision; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011379:Prognosis; D011788:Quality of Life; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000453:epidemiology / Q000601:surgery / Q000628:therapy*; D013965:Thyroidectomy / Q000379:methods; D013972:Thyrotropin / Q000037:antagonists & inhibitors
D007457:Iodine Radioisotopes; D013972:Thyrotropin